abrdn Life Sciences Investors (NYSE:HQL) Sets New 1-Year High – Should You Buy?

abrdn Life Sciences Investors (NYSE:HQL)’s share price hit a new 52-week high on Monday . The stock traded as high as $21.32 and last traded at $20.02, with a volume of 155198 shares trading hands. The stock had previously closed at $20.28.

abrdn Life Sciences Investors Price Performance

The stock’s 50 day moving average is $18.28 and its two-hundred day moving average is $17.39.

abrdn Life Sciences Investors Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Thursday, May 21st were issued a dividend of $0.56 per share. This represents a $2.24 dividend on an annualized basis and a yield of 11.3%. The ex-dividend date of this dividend was Thursday, May 21st.

Hedge Funds Weigh In On abrdn Life Sciences Investors

A number of hedge funds have recently modified their holdings of HQL. Geneos Wealth Management Inc. lifted its position in shares of abrdn Life Sciences Investors by 200.1% during the 2nd quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company’s stock worth $29,000 after buying an additional 1,529 shares during the period. Global Retirement Partners LLC grew its position in abrdn Life Sciences Investors by 187.8% in the fourth quarter. Global Retirement Partners LLC now owns 7,039 shares of the company’s stock valued at $118,000 after acquiring an additional 4,593 shares during the period. Mercer Global Advisors Inc. ADV bought a new stake in abrdn Life Sciences Investors in the fourth quarter valued at $177,000. Evolve Private Wealth LLC acquired a new position in abrdn Life Sciences Investors during the fourth quarter worth $199,000. Finally, Independent Financial Group LLC bought a new position in shares of abrdn Life Sciences Investors during the first quarter valued at $211,000. 32.21% of the stock is owned by institutional investors and hedge funds.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.